



Biotech Daily

Tuesday September 4, 2012

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: GENERA UP 9%, OPTISCAN DOWN 14%**
- * **HATCHTECH FDA MEETING FOR PHASE III HEAD LICE, EGG TREATMENT**
- * **ISONEA FREE SPRING TRIAL OF ASTHMA APPLICATION**
- * **FROSTBLAND TO DISTRIBUTE CELLMID ÉVOLIS HAIR PRODUCTS**
- * **CBIO TRADES AS INVION FROM TOMORROW**

MARKET REPORT

The Australian stock market fell 0.61 percent on Tuesday September 4, 2012 with the S&P ASX 200 down 26.2 points to 4,303.5 points.

Eleven of the Biotech Daily Top 40 stocks were up, 16 fell, nine traded unchanged and four were untraded. All three Big Caps fell.

Genera was the best, up 1.5 cents or 9.4 percent to 17.5 cents with 4,829 shares traded.

Allied Health climbed 8.3 percent; Cellmid was up 6.7 percent; Neuren was up 4.55 percent; Living Cell, Prima and Viralytics were up more than three percent; Prana rose 2.9 percent; Heartware and QRX were up more than one percent; with Clinuvel up 0.65 percent.

Optiscan led the falls, down 1.2 cents or 13.8 percent to 7.5 cents with 174,696 shares traded, followed by Sunshine Heart down 10.8 percent to 3.3 cents with 367,222 shares traded.

Compumedics and Phylogica lost more than seven percent; Acrux and Benitec fell more than five percent; Anteo and Reva were down more than three percent; Alchemia and Tissue Therapies shed more than two percent; Bionomics, Circadian, Mesoblast and Pharmaxis were down more than one percent; with Cochlear, CSL, Resmed, Sirtex and Starpharma down by less than one percent.

HATCHTECH

Hatchtech says a pivotal phase III trial of its Deovo head lice and egg treatment is on-track following end-of-phase II consultations with the US Food and Drug Administration.

Hatchtech said the consultations followed completion of the US phase IIb clinical trial demonstrating superior efficacy in 142 subjects with head lice infestation and the company was "on schedule" for a 2014 new drug application filing.

The company said that the FDA reviewed Hatchtech's data package, phase II protocols and the readiness for phase III trials in all disciplines and provided assessments of the company's detailed plans for the development program.

Hatchtech said the end-of-phase II consultations with the FDA was a "key part of seeking US marketing approval for prescription drug products".

Hatchtech chief operating officer Dr Lewis Schulz said he appreciated "the clear guidance from the FDA including the valuable, constructive feedback on several details of our pivotal study protocols".

"This reaffirms our proposed phase III program," Dr Schulz said.

"Significantly there were no surprises and we were very encouraged by the responses to our questions," Dr Schulz said. "The company remains on track to initiate the phase III program later this year."

Hatchtech chief executive officer Dr Ross Macdonald said the milestone was "another important achievement for Hatchtech".

"With the FDA, we have established a clear path to product registration and the market for Deovo, our next-generation head lice treatment product that will provide compelling advantages over currently available treatments," Dr Macdonald said.

Hatchtech is a private company.

ISONEA

Isona says it will provide its Asthmasense v.1.0.1 smartphone application, available free in Australia for the month of September to coincide with Asthma Awareness Week

Isona said the onset of Spring in September in Australia was regarded a peak asthma season.

The company said that one in 10 Australian adults had asthma and one in every nine children was affected.

Isona said the Asthmasense application enabled patients to log medications, symptoms and peak flow results, as well as set alerts for medication and lung function testing.

The company said that unlike most health applications which acted as passive journals Asthmasense v.1.0.1 alerted patients and carers if the condition was 'controlled' or 'poorly controlled' and was able to store and collate data, giving the user and their doctor or other medical professional access to this information.

Isona chief executive officer Michael Thomas said Spring was "a notoriously difficult time for Australian asthmatics, particularly children, who could be affected by typically higher pollen counts and allergy issues".

"By offering Asthmasense for free through September, we are increasing access to the most intelligent, easy-to-use asthma management [application] on the market during this troublesome season," Mr Thomas said.

Isona said that applications in development would incorporate the company's acoustic respiratory monitoring technology and diagnostic algorithms to enable lung function and wheeze rate testing via the smartphone device.

The company said the Asthmasense was available at Apple, Google and Amazon.

Isona was unchanged at six cents.

CELLMID

Cellmid says it has appointed Frostbland Pty Ltd as its exclusive distributor for the Australia and New Zealand pharmacy market for the Évolis hair growth products. Cellmid said Frostbland marketed and distributed beauty and healthcare products in pharmacies and department stores in Australia and New Zealand and had built several own brands, as well as distributing prestige and mass brands in skincare, cosmetics, fragrance and point-of-care diagnostics to more than 3,500 pharmacies in Australasia. The company said that Frostbland was privately owned with offices in Sydney, Australia and Auckland, New Zealand.

Cellmid said that Frostbland would take over all distribution responsibilities for the pharmacy market including sales, merchandising, product warehousing and dispatch as well as assisting with below the line advertising, allowing Cellmid to maintain its focus on its midkine product development, with new products in the pipeline.

The company said the exclusive distribution agreement had minimum monthly order requirements and sales targets and a term of three years extendable by mutual agreement.

Cellmid was up 0.1 cents or 6.7 percent to 1.6 cents.

INVION (FORMERLY CBIO)

Invion says that its name and ASX code will formally change from CBio, tomorrow September 5, 2012.

Invion said that from the market open, the company code will be IVX.

Invion was down 0.2 cents or 3.7 percent to 5.2 cents.